Skip to main content
Premium Trial:

Request an Annual Quote

Cyclica Raises C$23M in Series B Round

NEW YORK — Canadian informatics firm Cyclica said on Wednesday that it has raised C$23 million (US$16.9 million) in a Series B financing round.

The round was led by Drive Capital and included Chiesi Farmaceutici, GreenSky Capital, and members of Cyclica's management team.

Cyclica said it will use the funds to continue development of its artificial intelligence-based proteome-wide drug discovery platform, as well as to expand the platform's application within the pharmaceutical industry and into additional markets including agriculture. Cyclica said the money will also help accelerate its strategy of creating new drug-discovery programs via spinouts and joint ventures with research institutions.

Cyclica's flagship technologies include MatchMaker, which combines molecular biophysics and deep learning to predict the binding of new drug molecules to proteins, and pareto-optimal embedded modeling — or POEM — a machine-learning algorithm for generating ADMET prediction models.

In 2016, Cyclica raised C$2.4 million in a Series A round.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.